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Post-traumatic anxiety notably involves inﬂammation, but its causes and functional signiﬁcance are yet unclear. Here, we report
that failure of the innate immune system Toll-like receptor 9 (TLR9) to limit inﬂammation is causally involved with anxiety-
associated inﬂammation and that peripheral administration of speciﬁc oligonucleotide activators of TLR9 may prevent post-
traumatic consequences in stressed mice. Suggesting involvement of NFjB-mediated enhancement of inﬂammatory reactions
inthepost-traumaticphenotype,wefoundassociationofseruminterleukin-1bincreaseswithsymptoms severityandvolumetric
brain changes in post-traumatic stress disorder patients. In predator scent-stressed mice, the moderate NFjB-activating
oligonucleotides mEN101 and its human ortholog BL-7040, but not the canonic NFjB activator oligonucleotide ODN1826,
induced anxiolytic effects. In stressed mice, peripherally administered mEN101 prevented delayed stress-inducible serum
interleukin-1b increases while limiting stress-characteristic hippocampal transcript modiﬁcations and the anxiety-induced
EGR1-mediated neuronal activation. Attesting to the TLR9 speciﬁcity of this response, BL-7040 suppressed NFjB-mediated
luciferase in transfected cells co-expressing TLR9, but not other TLRs. Furthermore, TLR9 /  mice were mEN101 and BL-7040
resistant and presented unprovoked anxiety-like behavior and anxiety-characteristic hippocampal transcripts. Our ﬁndings
demonstrate functional relevance of TLR9 in protecting stressed mammals from overreacting to traumatic experiences and
suggest using oligonucleotide-mediated peripheral TLR9 activation to potentiate the innate immune system and prevent post-
traumatic inﬂammation and anxiety.
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Introduction
Post-traumatic stress disorder (PTSD) is a severe and long-
lasting anxiety disorder with recently increasing abundance
and social and economic signiﬁcance.
1 Apart from their
central nervous system impairments, PTSD patients suffer
multiple peripheral pathologies,
2 including persistent inﬂam-
mation. However, neither the mechanistic origin(s)
3 nor the
functional relevance of PTSD-associated inﬂammation have
been fully understood.
4 In search for answers, we considered
that reactions to trauma span somatic features associated
with the ecological context in which they evolved. Thus,
hormones released during stress prepare the immune system
to cope with physical injuries.
5 Therefore, anxiety patients
and rodents exposed to acute stressors both show elevated
serum levels of pro-inﬂammatory cytokines (for example,
interleukin (IL) -1b and IL-6).
6,7 However, apart from their
protective immune functions, such peripheral cytokines
access the brain and stimulate speciﬁc receptors.
8–10
Peripheral administration of IL1b, for example, potentiates
the consolidation of traumatic memories and the exaggerated
anxiety responses to subsequent mild stressors,
11,12 both
characteristic symptoms of PTSD.
13 Likewise, peripheral
administration of IL-6 elevates serum acetylcholinesterase
(AChE) levels,
14 limiting the cholinergic surveillance, which
prevents excessive inﬂammation under non-stressed condi-
tions.
15 Furthermore, the induction and penetration into the
brain of pro-inﬂammatory cytokines during stress reactions
may by itself induce anxiogenic effects,
9 creating a self-
propagating loop between psychological stress and immune
activation.Nevertheless,thevastmajorityofpost-traumatized
individuals do not develop PTSD; therefore, we predicted
that natural mechanism(s) should have evolved to tightly
regulate such peripheral reactions and restrain detrimental
cognitive and immune consequences, and that the emer-
gence of PTSD may becausally involved with inherited and/or
acquired impairments of such surveillance and regulatory
mechanisms.
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www.nature.com/tpThe master regulator of inﬂammation is the transcriptional
activator NFkB, the functioning of which can be manipulated
by CpG-including oligonucleotides (ODNs) through the
biosensor activities of Toll-like-receptors (TLRs).
16,17 TLRs
are pattern recognition receptors expressed on the cell
surface and/or in endosomal membranes of cells of the innate
immune system. By recognizing speciﬁc DNA motifs, espe-
cially those including CpG dinucleotides, TLRs can detect
pathogens
18 and inherent apoptotic processes releasing DNA
fragments.
16 Recent studies further attribute to TLRs the role
of regulators of neuronal survival and neuroplasticity, linking
their activation to cognitive tasks as well as behavioral
outcomes, for example, in Alzheimer’s disease.
19–21 By
adopting different modes of action, TLRs can lead to NFkB-
mediated pro-inﬂammatory reaction, interferon-mediated sti-
mulation of adaptive immunity and possibly an additional,
alternative anti-inﬂammatory activation of NFkB.
22,23 An
example is Toll-like receptor 9 (TLR9), which discriminates
unmethylated CpG dinucleotides, common in the genomes of
most bacteria and DNA viruses as well as in apoptotic host
DNA sequences, from the methylated ones in undamaged
mammalian DNA.
24 TLR9-driven pro-inﬂammatory activation
of NFkB may link between the innate and adaptive immune
systems by activating T and B lymphocytes through their
antigen and co-stimulatory receptors. The fact that NFkB also
activates an alternative homeostatic pathway, which leads to
suppression of pro-inﬂammatory cytokine production,
23,25
suggests a possibility of bi-directional effects. In this context,
several discriminative subtypes of TLR9 activators can
potentiate peripheral innate immune reactions, and are
classiﬁed into different subgroups. CpG-A ODNs tend to
spontaneously form large multimeric aggregates and are
therefore retained in the early endosome for relatively long
periods, inducing extended activation of the signal-transdu-
cing complex and robust type a interferon production.
18
CpG-B ODNs, however, remain monomeric and accumulate
inlateendosomes/lysosomes,stimulatingB-cellactivities,but
not interferon a production.
16 Other ODNs, may assume
mixed properties.
Based on the above knowledge, we surmised that if indeed
inﬂammation is functionally implicated in PTSD, the serum
cytokine levels in PTSD patients should be signiﬁcantly
associated with the severity of their anxiety symptoms and
pathophysiology hallmarks; using cultured cells, predator
scent-stressed mice and a series of TLR9-activating and
-blocking ODNs, we further challenged the hypothesis that
TLR9 can regulate peripheral immune reactions following
stress responses, thus restraining the detrimental cognitive
and immune consequences of traumatic experiences and
avoiding the emergence of PTSD.
Methods
Human patient recruitments. PTSD patients and healthy
volunteers were recruited from the psychiatric outpatient
clinics at the Soroka University Medical Center, Beer-Sheva
and the Tel Aviv Sourasky Medical Center, Tel-Aviv.
A written informed consent approved by the local Ethics
Committee was obtained from all participants; PTSD
diagnosis was ascertained by a board certiﬁed psychiatrist
(HS) and scored according to the Clinician-Administered
PTSD Scale.
26 Following recruitment to the study and diag-
nosis, full medical and psychiatric histories were obtained.
Whole-blood samples (5ml) were drawn into heparin-
coated plastic tubes, centrifuged (4000r.p.m., 41C, 30min),
and stored at  701C until use. Serum was prepared as
described.
27
Magnetic resonance imaging (MRI). Three-dimensional
structural MRI scans were acquired on a 1.5-T scanner
(Intera, Philips Medical Systems, Best, The Netherlands).
Two complete T1-weighted whole brain anatomical scans
were collected per subject with the following parameters:
repetition time ¼15, echo time¼4.6, ﬂip angle ¼301, matrix
size 256 256, ﬁeld of view 25.6cm, 150 sagittal slices
(1 1 1mm resolution). Images were preprocessed, the
averaged subject scans sub-cortically segmented and
volumes computed manually (pituitary) or by employing
Freesurfer release 3.0.2 (Freesurfer@nmr.mgh.harvard.
edu; all other regions).
Oligonucleotides. ODN1826, ODN2088 and ODN TTAGGG
were purchased from Invivogen (San Diego, CA, USA).
mEN101 (50-ctgcaatattttcttgca*c*c*-30) (stars denote 20-O-
methyl groups), complementary to a sequence in exon E2
of mouse AChE mRNA was from Mycrosynth (Balgach,
Switzerland). For TLR screening, recombinant HEK-293 cell
lines that stably express speciﬁc TLR proteins and an NFkB
promoter-driven luciferase reporter gene were induced with a
ligand speciﬁc to the expressed transgenic TLR (TLR2; PAM2
(100ngml
 1), TLR3; Poly I:C (100ngml
 1), TLR4; LPS K12
(100ngml
 1), TLR5; Flagellin (1mgml
 1), TLR7; R848
(10mgml
 1), TLR8; R848 (10mgml
 1), TLR9; ODN 2006
(CpG-B) (10mgml
 1)).
22 20ml ligand was used to stimulate
the cells in 200ml reaction volumes.
Animals. Adult TLR9  /  mice (kindly provided by
E. Galun, Jerusalem) and strain-matched wild-type C57/
B6J mice were housed four per cage, at 21±11C, in a 12-h
light/dark cycle. All animal studies were approved by the
Hebrew University’s committee for animal experiments
(Ethics number of research: NS-10205-4). See Supple-
mentary Methods for details on the ELISA, Real-time
RT-PCR and immunochemistry.
Behavioral paradigms. Mice were placed for 10min on
well-soiled cat litter. One week after exposure, animals were
tested as described
28 in the elevated plus maze (EPM) and
the acoustic startle response paradigms (TLR  /  only).
Shortly, mice were placed on the central platform and were
allowed to explore the maze for 5min. For startle response,
after a 5-min acclimatization period to a 68-dB white noise,
30 acoustic startle stimuli (110dB white noise of 40ms
duration with 30s or 45s inter-trial interval) were delivered
(SR-LAB System, San Diego Instruments, San Diego, CA,
USA). Habituation was calculated as the percent difference
between the ﬁrst and the last block of stimuli. To avoid order-
related differences, mice from the different groups were
intercalated in the behavioral tests.
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Translational PsychiatryStatistical analysis. Data in the tables are displayed as
mean±s.d. for the continuous variables and as number of
patients and percentage for categorical variables. The one-
way Kolmogorov–Smirnov test was used to assess the
distributions using SPSS/WIN (version 15.0, SPSS, Chicago,
IL, USA). The different biomarkers for patients and controls
were compared by Student’s t-test for normally distributed
variables and the Mann–Whitney U-test for non-normally
distributed variables (Presented as median and Interquartile
range). Correlations between parameters were determined
by the Pearson’s correlation test, a P-value of o0.05 was
considered statistically signiﬁcant (Table 1).
Results
Serum inﬂammatory markers correlate with symptoms
severity and volumetric brain changes in PTSD
patients. To test for inter-relationships between serum
inﬂammatory biomarkers and the severity of PTSD symp-
toms, we recruited both male (53%) and female (47%) PTSD
patients and matched controls for a retrospective study.
The patient demographics are summarized in Table 1. The
mean age in the PTSD and control groups was 37.9 (range
18–62) and 37.5 (22–59), respectively. PTSD diagnosis
was conﬁrmed using the Clinician-Administered PTSD Scale.
This included re-experience, avoidance and arousal scores,
each assessing a major symptomatic axis of PTSD.
26
Patients also presented co-morbid depression in the
Montgomery-A ˚sberg Depression Rating Scale (MADRS).
29
Compatible with previous reports,
30,31 patients presented
higher IL-1 (6.2±1.6 vs 5.2±1.0mgl
 1 serum, P¼0.002),
but not IL-6 (11.2±21.7 vs 6.0±3.5mgl
 1 serum, P¼0.159),
which presented higher variability. Nevertheless, given
the reports on the increase in PTSD of both IL-1 and IL-6,
we used the summated serum IL1b and IL6 levels
(designated ‘inﬂammatory load’, (Figure 1a)) to challenge
the possibility that peripheral inﬂammation is correlated with
PTSD symptoms severity. When divided into high and low
inﬂammatory load by splitting the group in the median
(Figure 1a), patients with high inﬂammatory load (n¼9)
showed increased re-experiencing (Po0.014, Figure 1b),
arousal (Po0.022), overall Clinician-Administered PTSD
Scale (Po0.05) and MADRS (Po0.02) scores compared
with PTSD patients with low inﬂammatory load (n¼10).
Avoidance scores (Po0.19) and the unrelated Pittsburgh
Sleep Quality Index score
32 showed no correlation to
cytokine concentration in the blood (Figure 1b), possibly
limiting the impact of their enhanced inﬂammation to their
autonomic response, but not behavioral manifestations that
are conditioning dependent.
Selective reduction in hippocampal volume is an estab-
lished neuro-anatomical marker of PTSD.
32,33 Magnetic
Resonance Imaging (MRI) tests, which were available for
several of the examined PTSD patients, depicted reduced
hippocampal volume, which was inversely correlated to their
serum IL1b levels (n¼5, r¼ 0.966, Po0.008, Pearson’s
correlation, Figure 1c1), though not to IL6 levels (r¼ 0.848,
P¼0.07). No correlations were found between IL1b levels
and the volume of other brain structures, such as the cerebral
cortex (r¼0.326, P¼0.593; Figure 1c3), amygdala (AMG),
thalamus, pallidum, brain stem and ventricles, attesting to the
speciﬁcity of the observed changes. Variable pituitary
volumes (Figure 1c2, r¼50, P¼0.391) might reﬂect hormo-
nal perturbations.
TLR9 activation ameliorates anxiety responses. The
apparent association between PTSD symptoms severity
and peripheral inﬂammation raised the question if periphe-
rally administered CpG-including oligonucleotide activators
of TLR9 and NFkB, or other ODNs modulators of inﬂam-
mation can modulate post-traumatic inﬂammation. We ﬁrst
exposed mice to the predator scent-mediated stress para-
digm
28 and treated them intraperitoneally (i.p.) with AChE
antisense ODN mEN101, which by suppressing AChE should
elevate acetylcholine levels, facilitating the cholinergic block-
ade of inﬂammation.
15 Of note, mEN101was shown to sup-
press immediate anxiety when i.p. administered to predator
scent-stressed mice
34 and to rapidly reduce both AChE and
anxiety symptoms when injected to the hippocampus of foot
Table 1 Population characteristics
Variable Patients Control P-value
n 37 37
Age, years (s.d.) 37.9 (12.4) 37.5 (11.0) 0.882
Gender, % (male) 46.8 53.2 0.675
Smoking, % 57.7 42.3 0.115
Interleukin-1, pgml
 1 (s.d.) 6.2 (1.6) 5.2 (1.0) 0.002
Interleukin-6, pgml
 1 (s.d.) 11.2 (21.7) 6.0 (3.5) 0.159
Acetylcholinesterase, mMmin
 1 ml (s.d.) 10.45 (0.58) 11.19 (0.64) 0.230
Cholinergic status, mMmin
 1 ml (s.d.) 17.43 (1.03) 18.66 (1.08) 0.225
CAPS
Total (s.d.) 82.0 (25.6) NA
Re-experience (IQR) 5 (4–5) NA
Avoidance (IQR) 6 (3.25–6.75) NA
Arousal (IQR) 5 (3–5)
PSQI (s.d.) 23.9 (7.2) NA
MADRS (s.d.) 24.1 (10.5) NA
Abbreviations: CAPS, Clinician-Administered PTSD Scale; IQR, Interquartile range; MADRS, Montgomery-A ˚sberg Depression Rating Scale; NA, not applicable;
PSQI, Pittsburgh Sleep Quality Index; s.d., standard deviation.
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Translational PsychiatryFigure 1 Inﬂammatory markers are correlated with Post-traumatic stress disorder (PTSD) severity. (a) Inﬂammatory markers are increased in PTSD patients compared
withcontrolsmatchedbyageandgender.(1)Interleukin(IL)1b.(2)IL6.(3)Inﬂammatoryload(summatedIL1bandIL6levels)inPTSDpatients,dividedintothosewithhigher
(HI) and lower (LI) loads (see text for details). (b) PTSD behavioral symptoms are increased in patients with high inﬂammatory load. (1) Clinician-Administered PTSD Scale
(CAPS) re-experience score. (2) CAPS arousal score. (3) Montgomery–A ˚sberg Depression Rating Scale (MADRS). (4) CAPS total score. (5) CAPS avoidance score.
(6)PittsburghSleepQualityIndex(PSQI).(c)IL1bcorrelatestoPTSDpatients’hippocampalvolume.TopScheme:Coronalandsaggitalimageshowingtheboundariesofthe
measuredstructures:(c1), (c2) and(c3). IL1b levels are inverselycorrelatedto averagehippocampal volume and positivelycorrelatedto pituitarygland volume,but notto the
cortical volume of PTSD patients. (*Po0.05, one-tailed t-test.)
TLR9 activation avoids post-traumatic anxiety
G Zimmerman et al
4
Translational Psychiatryshock-stressed mice.
35 The current study’s aim was to test the
long-term effects of ODN mEN101 and its human ortholog BL-
7040
36 on inﬂammation, anxiety and the inter-relationships
between them.
Tested ODNs or saline were i.p. injected to predator scent-
exposed mice for four consecutive days starting at exposure.
On the 7th day, pre-stressed mice with or without ODN
treatments were subjected to anxiety feature tests in the EPM
(Figure 2a). Stressed mice spent less time in the open arms
and entered them less frequently compared with naı ¨ve mice
(n¼11) (F6,111¼13.23, Po0.05; F6,111¼15.42, one-way
analysis of variance and Tukey post hoc test) (Figures 2b
and c). By day 7 post-stress, mice i.p. injected with 50mgkg
 1
mEN101 showed diminished stress-induced anxiety scores
compared with stressed mice (n¼27; Po0.001, Po0.01,
time in open arms and entry to open arms) (Figures 2b and c).
To test if this anxiolytic effect was co-mediated by TLR9,
we co-administered mEN101 with excess (500mgkg
 1)o f
the speciﬁc TLR9-inhibitor ODN2088 (n¼7). Co-treated
mice spent more time than stressed ones in the open arms
(Po0.001, Figure 2b), however, their number of entries to the
open arms remained unchanged (Figure 2c), suggesting that
blocking TLR9 interferes with the mEN101 anxiolytic effects,
but does not prevent it completely.
TLR9 activation abolishes delayed neuronal activation
in stress-related brain nuclei. Acute psychological stres-
sors increase neuronal activity in several stress-related brain
nuclei.
1,2,5 Two hours following stress exposure, predator
scent-stressed FVB/N mice (n¼3) showed increased
numbers of c-fos-stained neurons compared with naı ¨ve
controls in the hypothalamic paraventricular nucleus, the
hippocampal CA3 region and the AMG (Po0.05 for all,
Mann–Whitney U-test). Next, we exposed animals to
predator odor with or without mEN101 treatment, per-
formed EPM and startle anxiety tests 1 week later, and
tested the same regions in brains from animals killed 2h
afterwards. Previously stressed mice (n¼3) showed enhan-
ced neural activation, reﬂected by c-fos immunohisto-
chemistry, compared with naı ¨ve controls (n¼4). Elevated
c-fos was observed in the paraventricular nucleus, CA3 and
AMG (Po0.02 for all), amongst other brain areas. Adminis-
tered mEN101 completely abolished these delayed c-fos
increases (Po0.05 for all) (Figures 3a and b) (n¼4).
mEN101 thus efﬁciently prevented the long-term conse-
quences of predator stress. All of the stressed and saline-
treated animals showed more stained neurons per analyzed
area than any of the naı ¨ve ones, and all of the mEN101-
treated animals showed signiﬁcantly less stained neurons
than any of the saline-treated ones.
Anxiolytic TLR9 activation exerts systemic anti-inﬂam-
matory effects. Four days following exposure, stressed
FVB/N mice (n¼4) showed increased IL-6 serum levels
(Po0.02, Mann–Whitney test), but their serum IL-1b was
insigniﬁcantly elevated compared with saline treated ones
(Po0.15) (n¼5, Figure 3c). Compatible with previous
reports, which showed stress-induced elevation of IL-1b
7
and with thee anxiolytic effects of mEN101, its administration
decreased the observed post-stress levels of IL-6 (Po0.004)
and IL-1b (n¼4, Po0.02; Figure 3c). Similarly, adding
mEN101 and well established TLR9 activators and blocker
ODNs to cultured RAW macrophages identiﬁed mEN101 as
a TLR9 activator with low afﬁnity and mixed properties
(Supplementary Material and Supplementary Table 1).
TLR9 controls gene expression changes in stress-
related brain areas. Peripherally-produced cytokines pene-
trate the brain, activate interleukin receptors located in different
brain areas and may induce stress-related symptoms.
37,38
We hypothesized that, by abolishing cytokine upregulation,
Figure 2 mEN101-mediated activation of Toll-like receptor 9 (TLR9)
ameliorates predator scent stress effects. (a) Predator scent stress paradigm.
Seven days post-stress mice i.p. injected immediately before and consecutive 4
days after stress were subjected to EPM tests. (b) TLR9 activation is anxiolytic. On
day 7, cat scent exposed, saline injected C57B mice showed poorer EPM scores
than naı ¨ve animals. Injection of 50mgkg
 1 mEN101 ameliorated anxiety as
reﬂected by the length of time spent in open arms. These effects were abolished by
co-injection of 500mgkg
 1 of the TLR9 blocker ODN 2088. (c) Entries to open
arms. In this measure as well, mEN101 ameliorated anxiety; however, excess ODN
2088 did not change the no. of entries to open arms. Stars note statistically
signiﬁcant differences between the marked groups.
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Translational PsychiatryTLR9 activation could prevent at least part of the stress-related
changes in gene expression.
39 Therefore, we searched for
modiﬁcations in anxiety-related transcripts in the hippocampus,
a major structure of the limbic system. The Mouse Genome
Initiative (http://www.informatics.jax.org/) reports 259 genes
related to anxiety phenotypes. Of those, 11 hippocampal-
expressed genes were reported by others as involved in
abnormal EPM reactions. Four days following stress exposure,
we tested the expression levels of these transcripts in naı ¨ve
and stressed mice, mEN101-treated or untreated (n¼4 each
group). mEN101-mediated TLR9 activation reduced the
hippocampal expression of 3 out of these 11 EPM-related
transcripts in stressed mice, namely the GABA receptor a2
subunit transcript, the nicotinic receptor subunit a7 (CHRNA7)
and adenylate cyclase activating polypeptide 1 receptor
(Po0.001, Po0.03 and Po0.03 one-tailed t-test, respec-
tively). Furthermore, TLR9 blockade by ODN2088 reversed
these changes (Figure 3d). Other anxiety-related genes,
including the corticotrophin releasing hormone binding protein
(CHRBP), which controls HPA axis activation,
40 and the fear-
conditioning related genes protein kinase C b (PKCb)
41 and
calcium/calmodulin-dependent protein kinase 2a (CAMK2A)
42
showed no signiﬁcant changes (Figure 3d).
The early growth response gene 1 (egr1) is a transcription
factor activated by interleukin receptors, that operates as a
central mediator of inﬂammation in the brain.
43 Correspond-
ingly, pre-stressed mice showed higher egr1 expression
than naı ¨ve mice in brain nuclei expressing the IL-1b and
IL-6 receptors (for example, CA3 and AMG), as well as in
the paraventricular nucleus. TLR9-mediated abolishment of
peripheral cytokines should principally block interleukin
receptor activation and subsequent egr1 activation in the
brain.
10,38 Compatible with this prediction, peripheral TLR9
activation by mEN101-abolished egr1 increases in the
paraventricular nucleus and AMG, however, it had no effect
in the CA3 region (Supplementary Figure 1). Of note, a single
mEN101 dose administered immediately before the stressor
did not modify this response (Figure 3e), suggesting that
within this timeframe, mEN101 does not diminish the
threat perception and the acute reaction induced by potent
stressors.
Endogenous TLR9 activity modulates anxiety-related
gene expression and behavior. Our results demonstrated
that peripheral immune signals, which are restrained or
boosted by TLR9 activation signals outside the brain are
causally involved with the processing of psychological stres-
sors. This raised the question if consistent TLR9 activity
contributes to stress-related changes in brain gene expres-
sion and in behavior. To test if this was the case, we
compared C57/B6J mice with genetically ablated TLR9
44 to
strain-matched controls under baseline and stress condi-
tions using both EPM and acoustic startle response
(Figure 4a), and quantiﬁed their EPM-associated hippo-
campal transcripts.
In behavioral tests, naı ¨ve TLR9  /  mice (n¼6) exhibited
anxiety-induced increased EPM scores (Po0.002, one-tailed
t-test), reﬂecting greater basal anxiety than naı ¨ve C57/B6J
animals (n¼16). The TLR9  /  startle response, but not
startle habituation, was similar to that of C57/B6J mice
(Po0.07, Figure 4c), suggesting intact motor reﬂexes;
45
nevertheless, the general anxiety index (AI)
46 for TLR9  / 
mice was signiﬁcantly increased (Po0.035) (Figure 4d),
suggesting that inherent depletion of TLR9 reactions modiﬁes
anxiety-related behavior.
Hippocampi from naı ¨ve TLR9  /  mice showed upregula-
tion of GABA receptor a2 subunit transcript and down-
regulation of CHRBP (Po0.01, one-tailed t-test), both
predictingincreased HPAaxisactivation comparedwithnaı ¨ve
C57/B6 mice (n¼6, in each group).
40 Parallel decreases in
PKCb transcripts (Po0.05) suggested impaired contextual
fear learning.
41 Other tested stress-related transcripts
(for example, CHRNA7 and CAMK2A) were unaltered in
TLR9  /  hippocampi, attesting to the selectivity of the
observed differences (Figure 4b) and compatible with the
minimal changes in these transcripts in stressed C57BJ
mice (Figure 3d). Furthermore, unlike FVB/N
35 and C57/B6J
mice
34 (and the current report), TLR9  /  mice were totally
refractory to daily injections of 500mgkg
 1 mEN101, a dose
anxiolytic in similar short-term stress models of C57B6J
background
34 (Supplementary Figure 2).
Next, we repeated the predator scent stress experiment
(Figure 5a) using the human paralog of mEN101, BL-7040
(previously called hEN101), which was found to be therapeu-
tically effective in patients with the inﬂammation-associated
autoimmune disease myasthenia gravis.
47 Stressed C57B
mice injected with saline predictably entered less frequently
into the open arms and spent shorter time there than their
naı ¨ve peers. On the contrary, they spent more time in the
closed arms (n¼10 for all groups F6,69¼3.97, Po0.001;
F6,69¼12.09, Po0.0003; F6, 69¼10.07, Po0.001, one-way
analysis of variance and Tukey post hoc test) (Figure 5b).
Figure 3 Toll-like receptor 9 (TLR9) activation suppressesdelayedstress-relatedprocesses in brain andperiphery.(a) Theexperimentalparadigm.On day 4, serumwas
removed for measuring interleukin (IL) -1b and IL-6 levels (C) and hippocampal RNA was prepared for measuring changes in gene expression (D). On day 7, brain sections
werepreparedforc-fos(B)andegr-1labeling(E).(b)TLR9activationpreventsdelayedincreasesinthenumbersofcellspresentingc-fosinductioninresponsetomildstress.
Columns:Onday7,increasedc-fosexpressionwasfoundinparaventricularnucleus(PVN),CA3andamygdala(AMG)ofpre-stressed,butnotstressedandmEN101-treated
micerelativetonaı ¨vecontrols.(*Po0.05,Mann–WhitneyU-test).(c)TLR9activationabolishesstress-inducedIL1bandIL6increases(*Po0.02,Mann–WhitneyU-test).(d)
The elevated plus maze (EPM) malfunctioning-related transcripts GABA receptor a2 subunit transcript (GABRA2), CHRNA7, adenylate cyclase activating polypeptide 1
receptor 1 (ADCYAP1R1), but not PKCB, CHRBP and calcium/calmodulin-dependent protein kinase 2a (CAMK2A), were downregulated following stress, upregulated
following mEN101 injection and reduced to control levels under co-administration of the TLR9 blocker ODN2088 (*Po0.05, one-tailed t-test). (e) TLR9 activation does not
inhibit immediate stress reactions. Brain sections were assayed 2h after acute stress and c-fos expression was quantiﬁed by immunohistochemical staining followed by
counting labeled nuclei. Two hours after acute stress exposure, increased c-fos expression was found in the PVN, CA3 and AMG of both untreated (2) and mEN101-treated
mice (3) relative to naı ¨ve controls (1). Columns: No. of labeled nuclei per section (*Po0.05, Mann–Whitney U-test). Increased egr-1 expression in PVN, CA3 and AMG of
stressedmice(2,3)relativetonaı ¨vecontrols(1).NotethatTLR9activationbymEN101(3)abolishedsuchincreasesinPVNandAMG,butnotinCA3.Onesetofsectionsout
of 3 reproducible ones.
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with 50mgkg
 1 of the NFkB activator ODN1826, levels
of which induce robust inﬂammatory effects,
16 showed
stress-characteristic performance similar to that of stressed
non-injected mice. In contrast, the anti-human AChE ODN
BL-7040 (hEN101),
34,36 when daily i.p. injected at 50mgkg
 1
diminished stress-induced anxiety scores compared with
stressed mice (Po0.002, for EOA, TOA and TCA).
BL-7040 is targeted towards human AChE mRNA, which
differs from mouse AChE mRNA in the target sequence of
the tested ODN by 4 out of 20 nucleotides 5
1-CTGCc-Ac-G
TTc-TCc-TGCACC-30, lower-case nucleotides different. This
suggested that BL-7040 is unlikely to exert simple antisense
effects in i.p. injected mice. When we co-administered
BL-7040 with excess (500mgkg
 1) of the speciﬁc TLR9-
inhibitor ODN2088,
16 the BL-7040 anxiolytic effect was totally
abolished (Po0.003, Po0.007, Po0.004, for EOA, TOA and
TCA, respectively). However, when injected alone, ODN2088
exerted no anxiolytic effect (Figure 5b), indicating that
transient TLR9 blockade does not affect anxiety and
suggesting that the TLR9-mediated anxiolytic effect involved
alternative TLR9 activation rather than blockade. Also, both
Figure 4 Toll-like receptor 9 (TLR9)  /  mice exhibit changes in hippocampal gene expression, accentuated basal anxiety and subdued stress responses. (a) The
experimental paradigm. C57/B6 TLR9  /  mice and strain-matched controls were tested as in Figures 1 and 2. (b) Naı ¨ve TLR9  /  mice showed inherently different
transcript levels for the anxiety-related hippocampal GABA receptor a2 subunit transcript (GABRA2), CHRBP, and PKCB relative to matched controls (*Po0.05, one-tailed
t-test). Calcium/calmodulin-dependent protein kinase 2a (CAMK2A) and CHRNA7 transcripts were not altered. (c) TLR9  /  mice showed inherited differences in stress
responsiveness. Naı ¨ve TLR9  /  mice presented higher anxiety than matched C57/B6 controls, but their score differences after stress exposure were smaller (*Po0.05,
one-tailed t-test and Mann–Whitney U-test). (d) Anxiety Index of C57/B6 and TLR9  /  mice under different experimental conditions.
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treated mice, suggesting enhanced blockade of inﬂammation
due to ACh elevation
27,48 (Supplementary Material).
Discussion
Studying the underlying causes and consequences of post-
traumatic inﬂammation, we found association of serum
interleukin-1b increases with symptoms severity and volu-
metric hippocampal changes in PTSD patients, suggesting
functional involvement of NFkB. To challenge this implication,
we manipulated both inﬂammation and anxiety in predator
scent-stressed mice by peripheral administration of both
mEN101 and BL-7040, which emerged as selective TLR9-
mediating activators of the alternative NFkB pathway. Our
ﬁndings identify peripheral TLR9-mediated activation of
the alternative NFkB pathway as a continuous surveillance
mechanism for preventing post-traumatic inﬂammation and
anxiety, suggesting that failed interception of the vicious cycle
linking stress reactions with peripheral inﬂammation is a risk
for PTSD. Supporting this notion, the mouse BL-7040 paralog
mEN101 prevented post-traumatic hippocampal transcript
modiﬁcations and c-fos and EGR1-mediated neuronal
activation. Correspondingly, TLR9 /  mice were BL-7040
refractory and presented unprovoked anxiety-characteristic
behavior and hippocampal transcripts. Thus, both gain and
loss of inﬂammatory features in experimental mice supported
causal involvement for peripheral TLR9-mediated surveil-
lance in PTSD protection.
Psychological states are primarily processed by the brain,
which focused therapeutic development in this ﬁeld on agents
directly affecting neural function. Such is the case of the
GABAergic agonists and drugs affecting monoamine neuro-
transmitter metabolism.
49 In contradistinction, our current
work indicates a peripherally-initiated cascade that breaks the
feed-forward loop between the peripheral inﬂammatory
system and the brain to restrain subsequent stress impacts.
This further calls for speciﬁc precautions regarding potentially
detrimental psychological side effects of immune-stimulating
doses of TLR9 activators,
16 while representing a novel
approach for the development of anxiolytic compounds and
offering new indications for known TLR9 agonists under
clinical trials.
The observed serum suppression by BL-7040 of post-
stress IL-1b and IL-6 emerges as one of the ﬁrst steps in the
anxiolytic cascade. Slightly increased levels of peripheral
cytokines can both stimulate stress-related nuclei
7,29 and
facilitate the consolidation of fear memories.
8,31 Therefore,
cytokine decrease following TLR9 activation may mediate
TLR9 stress-suppressive effects. Moreover, the brain pene-
tration capacities of peripheral cytokines may explain the
observed increase in egr1 expression, and TLR9-mediated
immune regulation could block egr1 increase by mitigating
cytokine production.
The peripheral administration mode of the employed TLR9
agonists further suggests initiation of their psychoactive
effects in peripheral TLR9-expressing cells. Compatible with
this prediction, ODNs fail to cross the BBB owing to their high
polarity, which is a major obstacle for their use as neuroactive
agents.
50 In most performed studies only a tiny (o0.1%)
portion of the injected ODNs was found in brain tissue,
even when much higher doses than that used by us
were delivered.
50 The TLR9-mediated effects of ODN1826
and ODN2088 are reported elsewhere.
16 Correspondingly,
Figure 5 BL-7040-mediated activation of Toll-like receptor 9 (TLR9)
ameliorates long-term stress effects. (a) Predator-scent stress paradigm. Seven
days post-stress animals i.p. injected immediately before and 4 days after stress
were subjected to EPM tests. (b) BL-7040-mediated TLR9 activation is anxiolytic.
On day 7, cat scent-exposed, saline-injected C57B mice showed poorer EPM
scores than naı ¨ve animals. Injection of 50mgkg
 1 ODN1826 increased anxiogenic
behavior compared with saline injection. Inversely, 50mgkg
 1 of BL-7040
ameliorated anxiety. These effects were abolished by co-injection of 500mgkg
 1
ofODN2088(ENþ2088).Injectionof500mgkg
 1ofODN2088alonedidnotaffect
acute stress effects.
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pal transcript changes in mice by the speciﬁc TLR9 blocker
ODN2088, and TLR9  /  mice being refractory to the
mEN101 anxiolytic effect (the current report) both attests to
the TLR9-mediation of mEN101. Compared with their strain-
matched controls, TLR9  /  mice further showed a bimodal
behavioral imbalance of increased basal anxiety and dimin-
ished reaction to acute stressors, suggesting that physiologi-
cal TLR9 activation affects the ventral angular bundle–
basolateral amygdala pathway.
29 In contrast, the unchanged
acoustic startle response performance of TLR9  /  mice
suggests normal central amygdala–periaqueductal gray matter
connectivity.
31,51 Inherited Impairments in TLR9 functioning
may be pursued as causing parallel damages in humans.
The autonomic nervous system releases ACh continuously
from the vagus, thereby activating its receptors, especially
nAChRa7 in peripheral blood mononuclear cells, suppressing
production of pro-inﬂammatory cytokines.
48 A ﬁnely-
tuned balance between this brain-to-body signaling process
and the TLR9-mediated control of NFkB regulation of
pro-inﬂammatory cytokine secretion is essential for proper
regulation of this autonomous function. Our ﬁndings of
co-regulation by TLR9 of cholinergic and inﬂammatory
functions highlight a previously non-perceived powerful
mechanism for monitoring anxiety, distinct from the nA-
ChRa7-mediated cholinergic suppression of inﬂammatory
processes.
16 In conclusion, we showed that moderate
activation of TLR9 suppresses peripheral levels of brain-
penetrating cytokines and minimizes the behavioral conse-
quences of acute stress exposure. To the best of our
knowledge, this is the ﬁrst anxiolytic indication both for
peripherally acting drugs and for aptamers at large, adding
apreviouslyunforeseenrangeoftranslationalpsychiatryuses
for TLR9 therapeutics.
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